Development of an adverse outcome pathway network for reproductive toxicity endpoints to support identification of endocrine disrupters

Read full text Summarise with VIRAT
Authors: Terje Svingen, Monica Kam Draskau, Marie Louise Holmer, Johanna Zilliacus, Nora Bouftas, Anna Kjerstine Rosenmai, Eleftheria Maria Panagiotou, Emilie Elmelund, Hanna Katarina Lilith Johansson, Eleni Barmpari, Henrieta Hlisníková, Sofie Christiansen
+4 more Anna Opstrup Bindel, Majorie B.M. van Duursen, Pauliina Damdimopoulou, Anna Beronius
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Development of adverse outcome pathways (AOPs) can support the implementation of the EFSA–ECHA Guidance (2018) for identifying endocrine disruptors under EU Regulations 528/2012 and 1107/2009. However, their regulatory utility depends on them being fully developed and OECD‐endorsed, and in many cases their incorporation into more extensive AOP networks (AOPNs). To accelerate this process, EFSA has prioritized the creation of AOPNs spanning estrogenic, androgenic, steroidogenic, and thyroid (EATS) modalities, with an initial focus on mammalian reproductive toxicity driven by estrogenic, androgenic, and steroidogenic (EAS) disruption. In this context, this project developed a foundational AOPN capturing anti‐androgenic mechanisms that converge on key regulatory outcomes, including reduced anogenital distance, nipple retention, hypospadias, and impaired fertility. This AOPN currently includes 10 fully developed AOP. Additional developments under the project includes upstream networks for androgen, estrogen, and steroidogenesis modalties. The work establishes a modular architecture in which upstream molecular signaling pathways feed into shared developmental key events, thereby enabling integration of diverse mechanistic data and supporting transparent tracking of causal evidence. By mapping conserved pathways and identifying mechanistic nodes with high regulatory relevance, the framework also highlights critical knowledge gaps that hinder robust AOP expansion. The project incorporated standardized AOP‐Wiki methodologies to strengthen consistency in reporting and facilitate future network growth, while methodological advances such as refined weight‐of‐evidence procedures, systematic network‐mapping approaches, and strategies for building data‐rich key event relationships enhance reproducibility and evaluative confidence. Together, these developments can increase the practical value of AOPN for chemical evaluation and risk assessment, support alignment with emerging new approach methodologies (NAMs) for endocrine disruptor identification and provide a scalable foundation for future AOP and AOPN development.

Fields of Study & Subjects

Effects and risks of endocrine disrupting chemicals Animal testing and alternatives Agricultural safety and regulations

Publication details

Journal / source
EFSA Supporting Publications
Volume
23
Issue
3
Publication date
1 March 2026
Language
EN